Rhenovia Pharma

Rhenovia launches rare, orphan and neglected disease drug discovery

Monday, March 19, 2012 12:22 PM

Rhenovia Pharma, a biosimulation biotech company based in Mulhouse, France and Cambridge, Mass., has initiated drug research programs in rare, orphan and neglected neurodegenerative diseases.

More... »


Rhenovia Pharma opens first U.S. office

Wednesday, January 25, 2012 01:55 PM

Rhenovia Pharma, a biotechnology company specializing in biosimulation to aid discovery of treatments for brain diseases, has formed its first international subsidiary, Rhenovia Inc. The new operation will be based in Cambridge, Mass.

More... »


Rhenovia’s RHETOX project receives EUR 1.15 million in financing

Thursday, September 1, 2011 11:06 AM

Rhenovia Pharma has been selected by the French Armaments Directorate (DGA) and the General Directorate for Competitiveness, Industry and Services of the French Ministry of Economy, Finance and Industry (DGCIS) for inclusion in the RAPID program (Support Regime for Dual Innovation in SMEs). By this distinction, Rhenovia will lead a research program, named RHETOX, which will be conducted in partnership with the French Army’s Biomedical Research Institute (IRBA). Rhenovia will receive EUR 850,000 from a global funding amount of EUR 1.15 million.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs